Clinical Trials Browser

Recruiting × Lymphoma, B-Cell, Marginal Zone × zanubrutinib × Clear all

NCT04840602 2026-03-18

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Phase 2 Recruiting

92 enrolled

Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05100862 2026-03-18

MAHOGANY

Phase 3 Recruiting

780 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT06563596 2026-02-19

Epco, Zanu, Ritux for R/R FL or MZL

Phase 2 Recruiting

45 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT06350318 2026-02-05

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Phase 2 Recruiting

43 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT06647732 2026-01-15

Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)

Phase 2 Recruiting

42 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT07233720 2025-11-18

Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma

Recruiting

30 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT05326308 2025-09-23

ARIADNE

Recruiting

705 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT06859008 2025-08-05

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

37 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell